This summer’s U.S. FDA clearance of the oral pan-RAS inhibitor Rasonque (daraxonrasib) from Revolution Medicines Inc. provided hope for pancreatic ductal adenocarcinoma (PDAC) patients, and results ...
Evommune Inc. picked up rights outside of greater China to an oral, preclinical VAV1-directed molecular glue degrader (MGD) ...
Qyuns Therapeutics Co. Ltd. is expanding its partnership with Caldera Therapeutics through a potential $780 million deal for ...
Despite a concerted effort to speed trial setup, the number of patients taking part in industry-sponsored clinical studies in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results